Renny Abraham
Hematology & Oncology · Kettering, OHNPI 1891174397
Payments from drug & device makers
Across 45 payments — averaging $37.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$248
- Lilly USA, LLC$210
- Gilead$174
- Johnson & Johnson$150
- Jazz Pharmaceuticals Inc.$124
- E.r. Squibb & Sons, L.L.C.$122
- plus $660 from 17 others
What the payments were for
- Food & beverage$1,58694%
- Education$1016%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $248 |
| Lilly USA, LLC | 2 | $210 |
| Gilead(2 entities) | 3 | $174 |
| Johnson & Johnson(2 entities) | 4 | $150 |
| Jazz Pharmaceuticals Inc. | 1 | $124 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Boston Scientific | 1 | $111 |
| Novo Nordisk | 2 | $96 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $63 |
| Tempus AI, Inc | 2 | $55 |
| Bristol Myers Squibb | 2 | $47 |
| Caris MPI, Inc. | 1 | $43 |
| AVEO Pharmaceuticals, Inc. | 1 | $38 |
| ADC Therapeutics America, Inc. | 1 | $30 |
| Nuwellis, Inc. | 1 | $29 |
| Merck | 1 | $24 |
| Incyte Corporation | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Novartis | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$124
- Yescarta$123
- Reblozyl$122
- GENERAL - THERAPIES$111
- RETEVMO$108
How this compares
$1,688 in reported general payments places this provider in the 30th percentile of 450 hematology & oncology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 58 | $37,500 |
| EliquisApixaban | 13 | $9,909 |
| Ondansetron Hcl | 16 | $558 |
| Prochlorperazine Maleate | 23 | $321 |
| Anastrozole | 21 | $224 |
| Tamsulosin Hcl | 13 | $140 |
| Oxycodone Hcl | 11 | $117 |
| Prednisone | 66 | $110 |
| Acyclovir | 12 | $106 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11 | $9,90913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Kettering
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.